Dextech Medical AB
Dextech Medical AB engages in the development of drug candidates with application in urological oncology, primarily prostate cancer. The company's lead candidate, OsteoDex that has completed a phase IIb clinical trial for the treatment of bone metastases in castration-resistant prostate cancer, as well as in preclinical stage to treat breast and lung cancer, as well as multiple myeloma. The compa… Read more
Dextech Medical AB (LQ0) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.008x
Based on the latest financial reports, Dextech Medical AB (LQ0) has a cash flow conversion efficiency ratio of 0.008x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€193.00K) by net assets (€24.76 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Dextech Medical AB - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how Dextech Medical AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Dextech Medical AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Dextech Medical AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
AddTech Hub Public Company Limited
BK:ADD
|
0.043x |
|
Focus Dynamics Group Bhd
KLSE:0116
|
0.016x |
|
Vape Holdings Inc
NASDAQ:VAPE
|
-0.091x |
|
Aqua Bio Technology ASA
OL:ABTEC
|
-0.295x |
|
Bd Multimedia
PA:ALBDM
|
0.061x |
|
GROUP PAREF INH. EO 25
F:G5I
|
N/A |
|
Sintex Plastics Technology Limited
NSE:SPTL
|
-11.870x |
|
486630
KQ:486630
|
N/A |
Annual Cash Flow Conversion Efficiency for Dextech Medical AB (2022–2025)
The table below shows the annual cash flow conversion efficiency of Dextech Medical AB from 2022 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | €24.76 Million | €-1.11 Million | -0.045x | -64.42% |
| 2024-06-30 | €29.61 Million | €-807.62K | -0.027x | +39.70% |
| 2023-06-30 | €34.31 Million | €-1.55 Million | -0.045x | +12.07% |
| 2022-06-30 | €38.88 Million | €-2.00 Million | -0.051x | -- |